NACE 46.46 in FR. Official registry identity, filed financial evidence and a rounded indicative valuation range on one indexed company profile.
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on filed company accountsCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
You have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
The valuation for NUM RX combines official public company figures with Upswitch sector calibration. The owner can sharpen it with their own figures and context into a full, defensible valuation curve.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Operating as a business in NACE sector 46.46, NUM RX is registered in France. The company was founded in 2005, incorporated as a 5710.
NUM RX is listed in French National Business Register (RNE/INPI) under registry number 445151566. The public employee band is 02, a useful triage field for banks, credit analysts, and M&A acquirers. This profile consolidates official annual accounts into one indexable company dossier.
Companies in this NACE 46.46 band file annual accounts with INPI.
The most recently filed revenue (2025) stands at €1,979,265.
An indicative valuation band is available for NUM RX, based on filed company accounts. A free account lets the visitor refine it with current data and build a five-year outlook.
The most recent annual filing covers 2025 (period end 2025-03-31).
This page is refreshed whenever new regulator-filed data for NUM RX becomes available, consolidated into a single audit-grade view.
Public regulator-filed figures across 8 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202531 Mar 2025 | €1,979,265 | - | €789,128 | €537,230 | - |
| 202431 Mar 2024 | €1,946,154 | - | €1,769,174 | €1,420,297 | - |
| 202331 Mar 2023 | - | - | €1,650,817 | €1,169,557 | - |
| 202231 Mar 2022 | - | - | €1,560,466 | €981,632 | - |
| 202131 Mar 2021 | - | - | €1,501,195 | €850,517 | - |
| 202031 Mar 2020 | - | - | €1,056,158 | €622,716 | - |
| 201931 Mar 2019 | - | - | €883,515 | €548,954 | - |
| 201831 Mar 2018 | - | - | €881,513 | €470,236 | - |
NUM RX was founded in 2005 and is registered with French National Business Register (RNE/INPI), incorporated as a 5710.
NUM RX is registered under NACE 46.46: NACE 46.46. That places the business within the French cluster for this activity.
The most recently filed annual accounts cover fiscal year 2025 (period end 2025-03-31), publicly available via French National Business Register (RNE/INPI).
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for NUM RX may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
